Anchor Therapeutics' Series B Round

Anchor Therapeutics raised a round of funding on August 18, 2010.

Anchor Therapeutics is developing first-in-class pepducin drug candidates, novel molecules that can selectively target G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling.…

Articles about Anchor Therapeutics' Series B Round: